Reports
Sale
Global Haemophilia Treatment Market Share, Size, Growth, Analysis, Forecast: By Disease Type: Haemophilia A, Haemophilia B, Hemophilia C, Others; By Product Type: Recombinant Coagulation Factor Concentrates, Others; By Therapy Type; By Treatment Channel; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032
Global Haemophilia Treatment Market Outlook
The global haemophilia treatment market size reached a value of about USD 13.8 billion in 2023. The market is expected to grow at a CAGR of 7.5% during the forecast period of 2021-2030 to attain a value of USD 26.4 billion by 2032, driven by the rising prevalence of increased rapid advancement in the industry and increasing awareness among people.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haemophilia Treatment Market: Introduction and Overview
Haemophilia is a condition in which the blood clotting does not take place in the human body. The amount of blood clotting depends on the level of severity of the condition in the patient. Haemophilia happens when a human body lacks of blood clotting proteins hence, unable to clot the blood. Symptoms of haemophilia include bleeding in different parts of the body which may occur occasionally and spontaneously.
The market is growing rapidly and is expected to continue growing in the coming years as well. The major role is played by the governments and organizations that are continuously putting efforts in spreading awareness about haemophilia treatment globally. Also, the increased rate of research and development to determine the appropriate and effective treatments and therapies for the condition is among the major factors that are aiding the rapid growth of the global haemophilia market.
North America has been the leading region in the industry and contributed to a significant market share. It is expected to be doing the same for the forecast period as well. The reason behind North America being the leader of the treatment market is the rapid advancing of the technologies that are used to develop advanced products for the patients. The increasing prevalence of haemophilia is also a major reason for the rise of the global haemophilia treatment market share in North America.
Market Segmentations:
The haemophilia treatment market can be segmented into different categories such as disease type, product type, therapy type, treatment channel, distribution channel, and region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diseases Type
- Haemophilia A
- Haemophilia B
- Haemophilia C
- Others
Market Breakup by Product Type
- Recombinant Coagulation Factor Concentrate
- Plasma Derived Coagulation Factor Concentrate
- Desmopressin
- Antifibrinolytics Agents
Market Breakup by Therapy Type
- Replacement Therapy
- Immune Tolerance Induction Therapy
- Others
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Haemophilia Treatment Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haemophilia Treatment Market: Treatment Ladscape
There are significant research and developments going on in the market. Some of them have not been approved yet and some of them are in use already. However, the market is continuously developing and growing. The most recent key developments that have been introduced in the market to cure the haemophilia include the use of concentrates of plasma derived factors in the treatment. Liquid component of the blood is called plasma. It is commonly pale-yellow in colour and contains proteins like albumin, clotting factors, and antibodies. These plasma proteins are used in the composition of various factor concentrate therapeutic solutions. The human blood has to undergo several processes to split into different components such as clotting factors.
Other key drugs used in the treatment market are as follows:
- HEMLIBRA
Instead of directly replacing the lost clotting factor VIII, HEMLIBRA functions to replace factor VIII functions. It can be applied to haemophilia A patients to either stop or lessen the frequency of bleeding episodes. This can be administered by skin injections.
- DDAVP
The drug DDAVP and Stimate resemble a hormone that the body naturally produces. Factor VIII is kept in the bodily tissues and is released by the drugs. This can help people with mild and moderate haemophilia by self-increasing the level of factor VIII.
- Amicar
This is a drug that could be taken directly via mouth or in veins through injections. It could be in the form of a pill or a liquid. This drug helps in developing a stronger blood clot that does not break down easily.
Competitive landscape:
This report gives a detailed analysis of the following key players in the global haemophilia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds. The key players in the market are as follows:
- Novo Nordisk A/S
- Pfizer Inc
- Bayer AG
- Biogen Inc.
- CSL Behring
- Grifols SA
- Octapharma AG
- Kedrion S.p.A Ferring Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diseases Type |
|
| Breakup by Product Type |
|
| Breakup by Therapy Type |
|
| Breakup by Treatment Channel |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Haemophilia Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Haemophilia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Haemophilia Epidemiology (2016-2031)
5.3 Europe Haemophilia Epidemiology (2016-2031)
5.4 Asia Pacific Haemophilia Epidemiology (2016-2031)
5.5 Latin America Haemophilia Epidemiology (2016-2031)
5.6 Middle East and Africa Haemophilia Epidemiology (2016-2031)
6 Global Haemophilia Treatment Market Overview
6.1 Global Haemophilia Treatment Market Historical Value (2017-2023)
6.2 Global Haemophilia Treatment Market Forecast Value (2024-2032)
7 Global Haemophilia Treatment Market Landscape
7.1 Haemophilia Treatment Product Landscape
7.1.1 Analysis by Diseases Type
7.1.2 Analysis by Product Type
7.1.3 Analysis by Therapy Type
7.1.4 Analysis by Treatment Channel
7.1.5 Analysis by Distribution Channel
7.1.6 Analysis by Region
7.2 Haemophilia Treatment: Developers Landscape
7.2.1 Analysis by Year of Establishment
7.2.2 Analysis by Company Size
7.2.3 Analysis by Region
8 Haemophilia Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Haemophilia Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Haemophilia Treatment Market Segmentation
11.1 Global Haemophilia Treatment Market by Diseases Type
11.1.1 Market Overview
11.1.2 Hemophilia A
11.1.3 Hemophilia B
11.1.4 Hemophilia C
11.1.5 Others
11.2 Global Haemophilia Treatment Market by Product Type
11.2.1 Market Overview
11.2.2 Recombinant Coagulation Factor Concentrates
11.2.3 Plasma Derived Coagulation Factor Concentrate
11.2.4 Desmopressin
11.2.5 Antifibrinolytics Agents
11.3 Global Haemophilia Treatment Market by Therapy Type
11.3.1 Market Overview
11.3.2 Replacement Therapy
11.3.3 Gene Therapy
11.3.4 Immune Tolerance Induction Therapy
11.3.5 Others
11.4 Global Haemophilia Treatment Market by Treatment Channel
11.4.1 Market Overview
11.4.2 Public
11.4.3 Private
11.5 Global Haemophilia Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Global Haemophilia Treatment Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Haemophilia Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Haemophilia Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Haemophilia Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Haemophilia Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Haemophilia Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Novo Nordisk A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Biogen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 CSL Behring
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Grifols SA
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Octapharma AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Kedrion S.p.A.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Ferring Pharmaceuticals Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 F. Hoffmann-La Roche Ltd.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Haemophilia Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 13.8 billion in 2023.
The market is likely to grow at a CAGR of 7.50% during the forecast period of 2024-2032 to attain a value of USD 26.4 billion by 2032.
The different types include Haemophilia A, B, and C, among others.
The product types include recombinant coagulation factor concentrate, plasma derived coagulation factor, concentrate, desmopressin, and antifibrinolytics agents.
The therapies can be categorised into replacement therapy, gene therapy, and immune tolerance induction therapy, among others.
The treatment channels include private and public channels.
The distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy, among others.
Key players of the market are Novo Nordisk A/S, Pfizer Inc, Bayer AG, Biogen Inc., CSL Behring, Grifols SA, Octapharma AG, Kedrion S.p.A Ferring Pharmaceuticals Inc., and F. Hoffmann-La Roche Ltd.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER